The latest news and stats on sleep apnea, COPD, and out-of-hospital care from
ResMed, a world-leading connected health company. 

Latest news

Latest news

October 7, 2019

KANSAS CITY, Mo. — October 7, 2019 — Cerner Corporation (NASDAQ: CERN), a global health platform and innovation company, and ResMed (NYSE: RMD, ASX: RMD), a world-leading digital health...

October 3, 2019

SAN DIEGO, October 3, 2019 – ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2020 on Thursday, October 24,...

September 26, 2019

SAN DIEGO, September 26, 2019 – ResMed (NYSE: RMD, ASX: RMD) today announced that CEO Mick Farrell will ring the Opening Bell ® at the New York Stock Exchange (NYSE) on Monday, September 30,...

See all news releases

Fast facts - Landing Page

Fast facts

  • +2 MILLION
    myAir users self-monitor their CPAP treatment
  • +10 MILLION
    100% cloud connectable devices worldwide
  • +15 MILLION
    lives changed by a ResMed device, mask, or accessory

See all fast facts

In the news

In the news

July 26, 2019
Australian Financial Review
ResMed boss Mick Farrell has called out software and data as the critical focus for his business as it looks to drive its user-base up to 250 million people.
July 12, 2019
MD Magazine
In an interview with MD Magazine®, Carlos Nunez, chief medical officer of ResMed, provided suggestions for a primary care or specialist doctor looking to resolve their COPD patients’ therapy access.
July 9, 2019
Propeller Health CCO Chris Hogg discusses the danger of focusing on growth in digital health startups.

See all articles

Infographics - Landing Page


Learn about respiratory conditions, their effects on our health and communities,
and how ResMed helps millions live and breathe better.


See all infographics

Media resources - Gray, Left - Landing Page

Media resources

Find everything you need.
Ask us for more information.

See all resources

Media contacts - Gray, Right - Landing Page

Media contact

Jayme Rubenstein
(858) 836-6798


Email Alerts - Landing Page

Sign up to receive ResMed news releases when they publish.



ResMed provides a non-transferable, non-exclusive license to the copyrighted images, drawings and materials subject to the following Terms of Use.

All countries & languages